Esperion Therapeutics, Inc. (FRA:0ET)
2.654
+0.141 (5.61%)
At close: Jan 23, 2026
Esperion Therapeutics Revenue
Esperion Therapeutics had revenue of $87.31M USD in the quarter ending September 30, 2025, with 69.10% growth. This brings the company's revenue in the last twelve months to $303.80M, up 2.83% year-over-year. In the year 2024, Esperion Therapeutics had annual revenue of $332.31M with 185.66% growth.
Revenue (ttm)
$303.80M
Revenue Growth
+2.83%
P/S Ratio
2.59
Revenue / Employee
$999.35K
Employees
304
Market Cap
671.77M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332.31M | 215.98M | 185.66% |
| Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
| Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
| Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
| Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
| Dec 31, 2019 | 148.36M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
| Berliner Effektengesellschaft AG | 174.56M |
| Sedlmayr Grund und Immobilien AG | 139.01M |